LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.48
−0.34%Year over year
Reported trailing growth
- Revenue
- -29.0%
- EBITDA
- +46.7%
- EBIT
- +54.0%
- EPS
- +54.6%
- Free cash flow
- +22.4%
- Operating cash flow
- +21.8%
Forward estimates
Based on analyst estimates
- Revenue
- -68.3%
- EBITDA
- -57.5%
- EPS
- -40.4%
Three-year CAGR
- Revenue
- +610.3%
- EBITDA
- +77.5%
- EBIT
- +75.2%
- Net income
- +74.9%
- EPS
- +77.8%
- Free cash flow
- +62.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026